Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 3/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.54 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949560 | 0.85 | CDK8 (0.55) | CDK8FGFR1NTRK1MAP4K4AURKA | |
| SCHEMBL3025051 | 0.81 | CDK8 (0.49) | CDK8FGFR1FGFR3ADRA2AADRA1A | |
| SCHEMBL12448288 | 0.78 | FGFR1 (0.66) | CDK8FGFR1FGFR3ADRA2AADRA1A | |
| SCHEMBL837839 | 0.77 | FGFR1 (0.65) | CDK8FGFR1FGFR3ADRA2AADRA1A | |
| SCHEMBL3653363 | 0.75 | HDAC6 (0.45) | CDK8FGFR1FGFR3ADRA2AADRA1A | |
| SCHEMBL13702375 | 0.75 | HDAC8 (0.68) | CDK8MAP4K4FYNPIK3CGHDAC8 | |
| SCHEMBL835392 | 0.74 | FGFR1 (0.48) | CDK8FGFR1FGFR3NTRK1JAK2 | |
| SCHEMBL835840 | 0.74 | FGFR3 (0.73) | CDK8FGFR1FGFR3NTRK1FYN | |
| SCHEMBL3662014 | 0.74 | FGFR3 (0.43) | CDK8FGFR1FGFR3ADRA2AADRA1A | |
| SCHEMBL9950069 | 0.73 | ALDH1A1 (0.45) | CDK8FGFR1NTRK1MAP4K4AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143253-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143253-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143253-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| EP-2183027-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-20100204235-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20100204235-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20100204235-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| EP-2183027-A1 | ORGANIC COMPOUNDS | Novartis Ag (CH) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009013335-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009013335-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204235-A1 | ORGANIC COMPOUNDS | ALK, OR10J3, FFAR4 | CDK8 1828/4885FGFR1 20/4885FGFR3 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.